Acute Ischemic Stroke Diagnosis and Treatment Market By Type (Diagnostics, Treatment), By End User (Hospitals and Clinics, Ambulatory Surgery Centers, Diagnostic Laboratories and Imaging Centers, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032
The acute ischemic stroke diagnosis and treatment market was valued at $5.1 billion in 2022 and is estimated to reach $9.2 billion by 2032, exhibiting a CAGR of 6.1% from 2023 to 2032.
An acute ischemic stroke (AIS) is a medical emergency characterized by a sudden disruption of blood flow to a part of the brain, leading to a lack of oxygen and nutrients. This condition primarily results from the blockage or obstruction of a blood vessel supplying the brain, commonly due to a blood clot. The obstruction prevents adequate blood flow, causing damage to the brain tissue in the affected area. Acute ischemic strokes can manifest with various neurological deficits, such as sudden weakness, numbness, difficulty speaking, and impaired coordination. Thrombolytic medications, such as alteplase, and mechanical interventions like thrombectomy are commonly used to restore blood flow and mitigate the impact of an acute ischemic stroke.
Acute ischemic stroke (AIS) stands as the fourth leading cause of death and the primary cause of adult disability. This condition typically arises when a blood vessel obstruction occurs, resulting in irreversible brain injury and subsequent focal neurological deficits. The pharmacological approach to treating AIS revolves around intravenous thrombolysis using an alteplase, also known as recombinant tissue plasminogen activator (tPA). Alteplase administered intravenously facilitates thrombolysis by catalyzing the hydrolysis of plasminogen, forming the proteolytic enzyme plasmin.
The acute ischemic stroke diagnosis and treatment market has experienced significant growth owing to rise in prevalence of ischemic stroke. For instance, according to the World Stroke Organization Global Stroke Fact Sheet 2022, there were over 7.6 million new ischemic strokes each year and globally, over 62% of all incident strokes are ischemic strokes.
However, high cost of ischemic stroke diagnosis and treatment limits the market growth. For instance, according to World Stroke Organization (WSO), the Lancet Public Health article estimated treatment, rehabilitation, and indirect costs for stroke is more than $700 billion annually. Thus, high diagnosis and treatment cost negatively impact the market growth.
On the other hand, ongoing advancements in treatment options, including thrombolytic medications such as alteplase and innovative mechanical interventions like thrombectomy, drive the growth of the acute ischemic stroke market. These developments contribute to effective and timely management of acute ischemic strokes.
The acute ischemic stroke diagnosis and treatment market is segmented into type, end user, and region. By type, the market is segregated into diagnosis, and treatment. The diagnosis segment is further categorized into computed tomography, magnetic resonance imaging, carotid ultrasound, cerebral angiography, electrocardiography, echocardiography, and others. The treatment segment is bifurcated into thrombolytic therapy and mechanical thrombectomy. The thrombolytic therapy segment is further classified into tissue plasminogen activator, antiplatelet, and others. The mechanical thrombectomy segment is categorized into stent retriever and aspiration catheter, and combination (stent retriever and aspiration catheter). By end user, the market is divided into hospitals & clinics, diagnostic laboratories & diagnostic imaging centers, and others.
Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA).
Major key players that operate in the acute ischemic stroke diagnosis and treatment market are AstraZeneca plc, F. Hoffmann-La Roche Ltd., Boehringer Ingelheim International GmbH, GE Healthcare, Koninklijke Philips N.V., Siemens, Abbott Laboratories Medtronic plc, Johnson & Johnson, and Stryker Corporation. Key players have adopted product approval, partnership, and agreement as key developmental strategies to improve the product portfolio of the acute ischemic stroke diagnosis and treatment market.
Key Benefits For StakeholdersThis report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the acute ischemic stroke diagnosis and treatment market analysis from 2022 to 2032 to identify the prevailing acute ischemic stroke diagnosis and treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the acute ischemic stroke diagnosis and treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global acute ischemic stroke diagnosis and treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market SegmentsBy TypeDiagnostics
Technology
Computed Tomography
Magnetic Resonance Imaging
Carotid Ultrasound
Cerebral Angiography
Electrocardiography
Echocardiography
Others
Treatment
Type
Thrombolytic Therapy◦ Type
Mechanical Thrombectomy◦ Type
By End UserHospitals and Clinics
Ambulatory Surgery Centers
Diagnostic Laboratories and Imaging Centers
Others
By RegionNorth America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market PlayersBoehringer Ingelheim International GmbH
AstraZeneca plc
Abbott Laboratories
Stryker Corporation.
Siemens
Medtronic plc
Johnson & Johnson
F. Hoffmann-La Roche Ltd.
Koninklijke Philips N.V.
GE Healthcare
Please Note: It will take 7-10 business days to complete the report upon order confirmation.